Application of curcumin in preparing tumor multi-medicine drug-resistant prevention agent

A multi-drug resistance, curcumin technology, applied in antitumor drugs, pill delivery, drug combination and other directions, can solve the problem of no literature reports, and achieve the effect of increasing the concentration of chemotherapy drugs and improving the efficacy of chemotherapy

Inactive Publication Date: 2008-04-23
ZHEJIANG UNIV
View PDF0 Cites 16 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] It has been reported that curcumin can reverse P-gp-mediated tumor MDR in human drug-resistant tumor cells, but there is no literature report that it can prevent chemotherapeutic drug-induced drug resistance in human sensitive tumor cells

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of curcumin in preparing tumor multi-medicine drug-resistant prevention agent
  • Application of curcumin in preparing tumor multi-medicine drug-resistant prevention agent
  • Application of curcumin in preparing tumor multi-medicine drug-resistant prevention agent

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] Example 1: The effect of curcumin on preventing the increase of mdr1 mRNA expression in human K562 sensitive cells induced by doxorubicin

[0019] 1. Experimental materials:

[0020] Cell line: The human erythroleukemia cell line K562 used in this experiment was from American TypeCulture Collection (ATCC) company; RPMI-1640 culture medium and calf serum were purchased from American GIBCO company; curcumin standard was purchased from China Pharmaceuticals and Biological Products Laboratory; Adriamycin Hydrochloride for Injection was purchased from Zhejiang Hisun Pharmaceutical Co., Ltd.; Trizol reagent was purchased from American Life Technologies; RT-PCR kit was purchased from American Promega; mdr1 upstream and downstream primers and fluorescently labeled probes were purchased from from Shanghai Bioengineering Company.

[0021] Instrument: 5% CO 2 Constant temperature cell incubator (Heraeus, Germany); cell culture ultra-clean bench (Shanghai Lishen Scientific Instru...

Embodiment 2

[0073] Embodiment 2: the effect that curcumin prevents the increase of P-gp expression in human K562 sensitive cells induced by doxorubicin

[0074] 1. Experimental materials:

[0075] Cell line: The human erythroleukemia cell line K562 used in this experiment was from American TypeCulture Collection (ATCC) company; RPMI-1640 culture medium and calf serum were purchased from American GIBCO company; curcumin standard was purchased from China Pharmaceuticals and Biological Products Laboratory; Adriamycin Hydrochloride for Injection was purchased from Zhejiang Hisun Pharmaceutical Co., Ltd.; R-PE-labeled P-gp monoclonal antibody (R-PE-17F9) was purchased from BD Company, USA.

[0076] Instrument: 5% CO 2 Constant temperature cell incubator (Heraeus, Germany); cell culture ultra-clean bench (Shanghai Lishen Scientific Instrument Co., Ltd.); flow cytometer (Becton Dickson FACScan, USA); low-temperature ultracentrifuge (Heraeus, Germany) .

[0077] 2. Experimental method:

[007...

Embodiment 3

[0088] Embodiment 3: Curcumin can increase the accumulation level of doxorubicin in K562 cells

[0089] 1. Experimental materials:

[0090] Cell line: The human erythroleukemia cell line K562 used in this experiment was from American TypeCulture Collection (ATCC) company; RPMI-1640 culture medium and calf serum were purchased from American GIBCO company; curcumin standard was purchased from China Pharmaceuticals and Biological Products Laboratory; doxorubicin hydrochloride for injection was purchased from Zhejiang Hisun Pharmaceutical Co., Ltd.

[0091] Instrument: 5% CO 2 Constant temperature cell incubator (Heraeus, Germany); cell culture ultra-clean bench (Shanghai Lishen Scientific Instrument Co., Ltd.); flow cytometer (Becton Dickson FACScan, USA); low-temperature ultracentrifuge (Heraeus, Germany) .

[0092] 2. Experimental method:

[0093] 2.1 Cell Treatment

[0094] K562 cells at 1.5×10 5 The density of cells per well was seeded in a 6-well plate. Then add 0.5 μ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides an application of curcumin in preparation of tumor multi-drug drug-resistance preventing preparation. Its CAS mumber is 458-37-7, molecular weight is 368.37, chemical name is 1,7-bis-(4-hydroxy- 3-methoxyphenyl)-1,6-heptadiene-3,5-dione and its molecular formula is C21H2006. The curcumin drug prepared by said invention includes preparation allowable drug excipient and carrier.

Description

technical field [0001] The invention belongs to the use of natural plant monomer compounds, and relates to the new use of curcumin extracted from plants, in particular to the use of curcumin in preparing a preventive agent for tumor multi-drug resistance. Background technique [0002] Multidrug Resistance (MDR) refers to the cross-resistance of tumor cells to other anti-tumor drugs with different structures and mechanisms of action while they are resistant to one anti-tumor drug, which is the main reason for the failure of chemotherapy. . P-glycoprotein (P-gp) is the most important drug resistance protein mediating tumor multidrug resistance, and is the main cause of MDR in chemotherapy. [0003] At present, most of the research on anti-tumor multidrug resistance is based on the mechanism of MDR and after the formation of MDR, it is reversed with a specific reversal agent. However, after many tumor cells develop drug resistance, the abundance of drug-resistant proteins is v...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/12A61K9/08A61K9/10A61K9/16A61K9/20A61K9/48A61P35/00
Inventor 胡汛徐栋
Owner ZHEJIANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap